Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Net Cash Flow (2018 - 2025)

BioNexus Gene Lab's Net Cash Flow history spans 8 years, with the latest figure at -$208632.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 88.8% year-over-year to -$208632.0; the TTM value through Sep 2025 reached -$1.2 million, up 70.2%, while the annual FY2024 figure was -$1.7 million, 162.86% down from the prior year.
  • Net Cash Flow for Q3 2025 was -$208632.0 at BioNexus Gene Lab, up from -$767469.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $4.5 million in Q3 2023 and bottomed at -$1.9 million in Q3 2024.
  • The 5-year median for Net Cash Flow is -$188948.0 (2021), against an average of -$59441.1.
  • The largest annual shift saw Net Cash Flow skyrocketed 1278.54% in 2023 before it plummeted 12688.35% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $401759.0 in 2021, then rose by 5.68% to $424563.0 in 2022, then plummeted by 494.8% to -$1.7 million in 2023, then surged by 137.66% to $631218.0 in 2024, then crashed by 133.05% to -$208632.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Net Cash Flow are -$208632.0 (Q3 2025), -$767469.0 (Q2 2025), and -$840578.0 (Q1 2025).